Cardiorenal Effecs of Losartan in Kidney Transplant Recipients

The benefits of cardio and nephroprotective properties of treatment with drugs blocking the renin angiotensin aldosterone system in the general population has already been shown. There are no data on the cardiac and renal effects of this type of treatment in patients after renal transplantation. Therefore, the observational, case-control study was designed in a population of kidney transplant recipients. The study group consists of patients treated with antihypertensive drugs including Losartan at a minimum dose of 50mg. The control group consists of patients treated with antihypertensive drugs, without the renin angiotensin aldosterone system blockade. Blood pressure will be controlled in accordance with the current recommendations. The primary aim of this study is to determine whether, in renal transplant recipients with hypertension, losartan, angiotensin II receptor antagonist improves cardiovascular and graft outcome i.e. reduces incidence of cardiovascular complications and slows progression of graft insufficiency. Secondary objective is to determine whether losartan 1. delays the occurrence of cardiovascular complications, 2. slows progression of graft insufficiency, 3. is the safe drug in renal transplant recipients, 4. decrease albuminuria and other surrogate markers of graft injury or cardiovascular involvement.